|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||5.90 / 25.17|
Management to Host Conference Call Thursday, June 8 at 8:30 am ET
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in NewLink Genetics Corp , where a total of 2,935 contracts have traded so far, representing approximately 293,500 underlying shares. That amounts to about 47.5% of NLNK's average daily trading volume over the past month of 617,940 shares.
Investors considering a purchase of NewLink Genetics Corp shares, but tentative about paying the going market price of $11.10/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $10 strike, which has a bid at the time of this writing of $1.45.
Loxo Oncology, NewLink Genetics and BioCryst Pharmaceuticals were among the biotech movers in premarket trading on Monday.
The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of NewLink Genetics Corporation ("NewLink" or the "Company") (NASDAQ:NLNK) into potential breaches of fiduciary duty...
Management to Host Conference Call Today at 8:30 a.m. ET
Here's a technical look at how to play six stocks trending higher with strong volume.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at NewLink Genetics Corporation ("NewLink" or the "Company") (NASDAQGM:NLNK).
59% Objective Response Rate (ORR) and 80% Disease Control Rate (DCR) in 51 Patients with Non-ocular Melanoma
Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with NewLink Genetics Corp . The average 12-month price target for NLNK — averaging the work of 6 analysts — reveals an average price target of $22.33/share.
The broad development plan across five different types of cancer widens Incyte's lead over other IDO inhibitors in clinical development.
In recent trading, shares of NewLink Genetics Corp have crossed above the average analyst 12-month target price of $18.17, changing hands for $19.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Interim Phase 2 Clinical Results of IDO Pathway Inhibitor, Indoximod Selected for an Oral Presentation During the Clinical Trial Plenary Session
Management to Host Conference Call and Webcast Today at 8:30 a.m. ET
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in NewLink Genetics Corp , where a total volume of 1,845 contracts has been traded thus far today, a contract volume which is representative of approximately 184,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 68.5% of NLNK's average daily trading volume over the past month, of 269,305 shares.